Varicella Zoster Virus vasculopathy in a patient treated with immune checkpoint inhibitor for lung cancer

Rev Neurol (Paris). 2019 Jan-Feb;175(1-2):95-97. doi: 10.1016/j.neurol.2018.03.013. Epub 2018 Oct 8.

Authors

R Ursu¹, A Roumi², K Chouahnia³, V Altmayer², S Cuzzubbo⁴, A F Carpentier⁴

Affiliations

¹ Service de neurologie, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), 1, avenue Claude-Velfaux, 75010 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France. Electronic address: renata.ursu@aphp.fr.
² Service de neurologie, hôpital Avicenne, Assistance publique-Hôpitaux de Paris (AP-HP), Bobigny, France.
³ Service d'oncologie médicale, hôpital Avicenne, Assistance publique-Hôpitaux de Paris (AP-HP), Bobigny, France.
⁴ Service de neurologie, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), 1, avenue Claude-Velfaux, 75010 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France.

PMID: 30309661
DOI: 10.1016/j.neurol.2018.03.013

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenocarcinoma of Lung / drug therapy*
Cell Cycle Checkpoints / immunology
Encephalitis, Varicella Zoster / complications
Encephalitis, Varicella Zoster / diagnosis
Herpesvirus 3, Human / physiology*
Humans
Immunologic Factors / adverse effects
Immunologic Factors / therapeutic use
Lung Neoplasms / drug therapy*
Male
Middle Aged
Nivolumab / adverse effects
Nivolumab / therapeutic use*
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / immunology
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use
Varicella Zoster Virus Infection / complications*
Vasculitis / virology*
Virus Activation / drug effects
Virus Activation / immunology

Substances

Immunologic Factors
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Protein Kinase Inhibitors
Nivolumab